Regeneron Pharmaceuticals, Inc. $REGN Stock: Sepio Capital LP Lowers Stake

Sepio Capital LP lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,639 shares of the biopharmaceutical company’s stock after selling 778 shares during the quarter. Sepio Capital LP’s holdings in Regeneron Pharmaceuticals were worth $2,760,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Orbimed Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $11,358,000. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $5,682,636,000. Contravisory Investment Management Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $6,327,000. Oxbow Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $3,342,000. Finally, Deutsche Bank AG purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $323,249,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $819.09 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $572.75 and a 12 month high of $859.34. The stock has a market cap of $84.33 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.37 and a beta of 0.16. The company’s 50 day moving average is $791.83 and its two-hundred day moving average is $722.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $12.81 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 48.87 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on REGN shares. The Goldman Sachs Group boosted their price objective on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Evercore lifted their target price on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Robert W. Baird lifted their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. Finally, BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $846.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.